Protalix Biotherapeutics Inc (PLX)
EBITDA Growth
219.29%
Quarterly · Period ending:
PLX EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported219.29%period ending
Latest reported219.29%period ending
PLX Quarterly EBITDA YoY % (-281.82% → 219.29%)
Year-over-year change
High-resolution chart · PNG
PLX ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 219.2905% | |
| 743.1361% | |
| -152.325% | |
| -37.5755% | |
| 213.7453% | |
| 15.9413% | |
| 243.3976% | |
| 568.6583% | |
| -107.4653% | |
| -100.3488% | |
| -133.6543% | |
| 64.0678% | |
| 578.1679% | |
| -43.5622% | |
| 51.0392% | |
| -76.5293% | |
| 49.2229% | |
| 53.907% | |
| -245.4347% | |
| 30.4669% | |
| -368.4154% | |
| -157.5303% | |
| 14.9355% | |
| -98.6226% | |
| 65.7687% | |
| 206.7423% | |
| -76.8414% | |
| 64.871% | |
| 12.7299% | |
| -7.6269% | |
| 196.649% | |
| 57.4293% | |
| -256.7561% | |
| 91.8878% | |
| -51.6411% | |
| -23.4865% | |
| 142.6859% | |
| -696.0737% | |
| 24.7392% | |
| -34.1142% | |
| -89.4001% | |
| -49.9156% | |
| -73.437% | |
| 18.1039% | |
| -11.0011% | |
| 15.3874% | |
| 32.222% | |
| -13.1507% | |
| 25.1179% | |
| -65.6906% | |
| -0.5515% | |
| -2.0869% | |
| -156.2654% | |
| 34.1577% | |
| -16.6814% | |
| 40.9403% | |
| 239.4949% | |
| -23.4375% | |
| 53.8251% | |
| -282.2244% | |
| 14.6773% | |
| 43.958% | |
| -18.9232% | |
| 63.0208% | |
| -64.1786% | |
| -62.0742% | |
| -143.8662% | |
| 12.6314% | |
| -17.9336% | |
| 23.6794% | |
| -2.1931% | |
| -3.1564% | |
| 50.185% | |
| -64.456% | |
| 36.3906% | |
| -154.6579% | |
| -170.772% | |
| -137.102% | |
| -34,779.8897% | |
| -6,660.4849% | |
| -16,500.6359% | |
| -14,067.3571% | |
| 18.7062% | |
| 18.2239% | |
| 65.8727% | |
| 63.4045% | |
| 34.281% | |
| -32.9033% | |
| -93.495% | |
| 14.0864% | |
| 6.9995% | |
| 7.6678% | |
| 16.038% | |
| 14.9472% | |
| 66.3782% | |
| 39.052% | |
| 43.3102% | |
| -243.593% | |
| 28.98% | |
| -276.7853% |